Heather A. Wakelee, MD

Heather A. Wakelee, MD, discusses recent research investigating antiangiogenic agents and checkpoint inhibitors in the frontline for patients with <em>EGFR</em>-positive non&mdash;small cell lung cancer. The most promising data were demonstrated in the phase III IMpower150 trial.

Heather A. Wakelee, MD, discusses the use of osimertinib as a frontline treatment option for patients with <em>EGFR</em>-positive lung cancer.

Heather A. Wakelee, MD, discusses a study utilizing liquid biopsies in patients with non-small cell lung cancer who harbor EGFR mutations.